CSL Limited

The CSL Centenary Fellowships for early-mid career medical researchers are high-value awards available to Australians who wish to continue a career in medical research in Australia. Two individual five-year $1.25 million fellowships are awarded each calendar year.

This $25 million program was established by CSL Limited in its Centenary year to support Australia’s best and brightest biomedical researchers—fostering excellence in medical research by supporting mid-career scientists to pursue world-class research at an Australian institution.

The 2020 Fellows will be announced on Thursday 10 October, 2019.

For more information, contact Niall Byrne on niall@sciencienpublic.com.au 0417 131 977 or (03) 9398 1416.

More about the Fellowships at: www.csl.com.au/centenary/fellowships.htm

CSL Limited is a global specialty biotechnology company that researches, develops, manufactures and markets products to treat and prevent serious human medical conditions.

$2.5 million CSL Centenary Fellowships announced

Curing the ‘hidden malaria’ in Asia/Pacific (Darwin)

A path to personalised treatment for most cancers (Adelaide)

Two Australian scientists have each been awarded AUD$1.25 million CSL Centenary Fellowships over five years to improve treatments for two of the world’s biggest health challenges: malaria and cancer. The Fellowships will be presented in Perth at the Australian Academy for Health and Medical Research Gala Dinner on 10 October.

[continue reading…]

Curing the “hidden” malaria

Dr Kamala Thriemer, Darwin

Dr Kamala Thriemer will use her $1.25 million CSL Centenary Fellowship to develop and optimise treatment programs against vivax malaria in SE Asia and the Horn of Africa.

Photo credit: Stepping Stone Films

Vivax malaria is the second largest cause of malaria deaths and is hard to treat as the parasite can hide in the liver and re-emerge months later. Her studies have shown that as few as one in ten patients successfully complete the long course of treatment.

Kamala is a public health researcher at the Menzies School of Health Research in Darwin.

[continue reading…]

A path to personalised treatment for most cancers

Associate Professor Daniel Thomas, Adelaide

Dan Thomas has developed new ways to identify a cancer’s weakness and target it with personalised treatment. He’s already treating acute myeloid leukaemia patients in Adelaide.

Photo credit: Stepping Stone Films

His $1.25 million CSL Centenary Fellowship will facilitate his return from Stanford University to the South Australian Health and Medical Research Institute (SAHMRI) and The University of Adelaide.

Daniel began his academic career with a PhD in haematology from the University of Adelaide.

[continue reading…]

Brisbane scientists awarded $2.5m in first CSL Centenary Fellowships

  • Is long term memory stored in DNA, and what does it mean for Alzheimer’s?
  • Changing the odds from one in 10 for older leukaemia patients
  • Scientists available for interview.  

Two Brisbane scientists have each been awarded an AUD$1.25 million, five-year CSL Centenary Fellowship to further research that aims to help patients beat leukaemia and examine the origins of memory to better understand Alzheimer’s disease.

Full profiles, photos, HD footage available:

CSL media release: www.scienceinpublic.com.au/media-releases/csl-fellows

Overlay available via Dropbox: www.dropbox.com/sh/aujr04spwvx7ecp/AAArPfLhh8vXMaZhEEXzSAG9a?dl=0 

For more email Niall Byrne niall@scienceinpublic.com.au or call Toni Stevens (03) 9398 1416, 0401 763 130

Professor Geoff Faulkner and Associate Professor Steven Lane are the inaugural Fellows in a $25 million program established by CSL in its centenary year to support Australia’s best and brightest biomedical researchers—fostering excellence in medical research by supporting mid-career scientists to pursue world-class research at an Australian institution.

Professor Geoff Faulkner from the University of Queensland thinks long-term memory might be stored in our brain’s DNA and he’ll test his theory in brains affected by Alzheimer’s.

Today, 85 per cent of children with leukaemia can be cured, but the outlook for patients over 60 is bleak, with only 10 per cent surviving beyond one year as their cancer adapts to weather the storm of standard chemotherapy treatments. Steven wants to change that outlook.

[continue reading…]

Australian Scientists awarded $2.5m in support of ground-breaking research into Alzheimer’s Disease and Leukaemia

csl-100-logo-downloadedCSL Limited Media Release

Two Australian scientists have each been awarded an AUD$1.25 million, five-year CSL Centenary Fellowship to further research that aims to help patients beat leukaemia and examine the origins of memory to better understand Alzheimer’s disease.

Professor Geoff Faulkner and Associate Professor Steven Lane are the inaugural Fellows in a $25 million program established by CSL in its centenary year to support Australia’s best and brightest biomedical researchers—fostering excellence in medical research by supporting mid-career scientists to pursue world-class research at an Australian institution.

[continue reading…]

Are memories stored in DNA?

Geoff Faulkner— Mater Research Institute-University of Queensland (MRI-UQ) and Queensland Brain Institute (QBI)

2017 CSL Centenary Fellowship; $1.25 million over 5 years

geoff_faulkner_2-tomrGeoff Faulkner is testing a bold idea— he thinks long-term memory might be stored in our brain’s DNA. If he’s right, it will revolutionise both our understanding of life’s blueprint and how we manage diseases like schizophrenia and Alzheimer’s.

There’s DNA in every human cell called ‘junk’ or ‘non-coding’ DNA because our bodies don’t use it to generate proteins, the building blocks of life.

The strange thing is, this DNA makes up over 98 per cent of our genome. Surely it must do something. The question is: what?

Geoff Faulkner has been studying this question for years with his team from the MRI-UQ. Now, working with the Queensland Brain Institute (QBI), Geoff’s inaugural CSL Centenary Fellowship will help him delve deeper, using brains bequeathed by Alzheimer’s patients.

[continue reading…]

Improving survival for patients with acute leukaemia

Steven Lane—QIMR Berghofer Medical Research Institute

2017 CSL Centenary Fellow, $1.25 million over five years

steven_lane-tomrLeukaemia is one of Australia’s deadliest types of cancer. However, as Steven Lane knows, it’s not just one type—it’s hundreds of different types, each with its own genetic fingerprint.

This variation means some types of leukaemia are treatable, whereas others quickly develop resistance. Today, 85 per cent of children with leukaemia can be cured, but the outlook for patients over 60 is bleak—only 10 per cent survive beyond one year.

Steven wants to change that outlook. Together with his team at the QIMR Berghofer Medical Research Institute in Brisbane he has developed the capacity to rapidly profile the genetics of leukaemia types and model them in the lab.

[continue reading…]

CSL Announces $25 million Centenary Fellowship Program

CSL Media Release

fellowship-web1CSL is proud to announce the establishment of a new flagship $25 million fellowship program for early stage and translational research in Australia.

The announcement was made last night by CSL’s Chief Executive Officer, Mr Paul Perreault, at the CSL Centenary Celebration Gala. Mr Perreault also announced that the highly respected molecular biologist, Professor Ashley Dunn, will Chair the Selection Committee.

[continue reading…]